50 mL of Olive Oil a Day Changed Gut Bacteria in Women with Fibromyalgia

Fibromyalgia affects an estimated 2 to 4% of the global population, predominantly women, and remains one of medicine's more stubborn puzzles: no molecular diagnostic test, no reliably effective treatment, and a mechanism that researchers are still piecing together. One increasingly compelling thread involves the gut microbiome. Dysbiosis, an imbalance in gut bacterial communities, appears to promote neuroinflammation and may contribute to the central sensitization that drives chronic pain. A new randomized controlled trial published in June 2026 tested whether a Mediterranean diet supplemented with extra virgin olive oil (EVOO) could shift that microbial picture in meaningful ways.

What 50 mL of EVOO Daily Did to Fibromyalgia Gut Bacteria

The trial enrolled 250 women, 206 with fibromyalgia and 44 healthy controls, all already following a Mediterranean-style diet. After a 14-day washout on refined olive oil, participants were randomized in a double-blind design: one group consumed 50 mL per day of EVOO for six months, the other continued with refined olive oil as placebo. Stool samples were collected at baseline, three months, six months (end of intervention), and 12 months (six months after intervention ended). Gut microbiota composition was analyzed using metagenomic sequencing of the V3-V4 regions of 16S rDNA, processed through R-based bioinformatic pipelines. Of the original cohort, 190 women completed the full protocol.

The EVOO group showed a series of taxon-level shifts over the course of the study. At three months, levels of Bacteroides fragilis, a bacterium that produces gamma-aminobutyric acid (GABA), a neurotransmitter relevant to pain modulation and sleep, increased in fibromyalgia patients on EVOO. Anaerotruncus colihominis and related taxa also rose at this timepoint. At six months, Pseudoruminococcus and Dysosmobacter showed greater increases in the EVOO group, while Ruminococcus bromii, a fiber-degrading bacterium, decreased relative to controls. Notably, Faecalibacterium prausnitzii and Roseburia intestinalis, two butyrate-producing species frequently cited as markers of gut health, were transiently lower in the EVOO group during the intervention but rebounded afterward.

Perhaps the most intriguing signal came after the intervention ended. At the 12-month mark, six months after participants stopped their assigned oil, Anaerostipes hadrus, another butyrate producer, showed greater increases in fibromyalgia patients who had received EVOO. The Eggerthellaceae family, including Adlercreutzia equolifaciens, a species that produces equol, a metabolite with antioxidant and estrogen-like properties, also increased more in that group. A delayed or carry-over effect of this kind is unusual and worth watching in future work.

Why Gut Dysbiosis Matters So Much for Fibromyalgia Patients

The microbial shifts documented here sit against a backdrop of growing evidence that the gut-brain axis is genuinely implicated in fibromyalgia. A Mendelian randomization study has established causal associations between specific gut microbiota genera and fibromyalgia, pointing to mechanisms that run through the gut-brain axis rather than reflecting coincidental correlation. When the gut barrier becomes permeable, bacterial lipopolysaccharides can translocate into systemic circulation, triggering microglial activation and amplifying central pain signals. Certain bacteria, including Lactobacillus and Bifidobacterium species, modulate the hypothalamic-pituitary-adrenal axis, influencing anxiety and stress reactivity. Reduced butyrate production, consistent with the lower Faecalibacterium prausnitzii and Roseburia levels documented in fibromyalgia patients at baseline, can impair gut barrier integrity and reduce anti-inflammatory short-chain fatty acid signaling.

The baseline data in this trial reinforced that picture. Fibromyalgia patients showed lower microbial diversity and richness than healthy controls before any intervention began, consistent with prior studies documenting gut microbiome disruption in chronic pain conditions. Extra virgin olive oil, rich in phenolic compounds, has been shown to reduce pathogenic bacteria and selectively promote beneficial species, making it a plausible tool for nudging that dysbiosis.

How the Double-Blind Design Strengthened the Evidence

Using refined olive oil as the placebo was a methodologically sensible choice. It allowed blinding while controlling for the broader Mediterranean dietary pattern that both groups followed. The four-timepoint sampling schedule, including a follow-up six months after the intervention ended, is stronger than most dietary microbiome trials, which often stop at the end of the active period. The sample size calculation was prevalence-based, targeting at least 198 fibromyalgia patients for 95% confidence, and the final analytic cohort of 190 was close to that target.

The double-blind structure also matters because fibromyalgia is notoriously susceptible to placebo effects, particularly on subjective outcome measures. Separating perceived benefit from measurable microbial change is essential for understanding what, if anything, EVOO is actually doing.

What the Study Could Not Resolve

Despite the microbial shifts, neither group showed significant changes in clinical outcomes over time. Scores on the SF-36 quality-of-life measure and the Fibromyalgia Impact Questionnaire Revised (FIQR) did not move meaningfully. The authors suggest several reasons: the microbiome shifts may have been too modest to translate into symptom relief, six months may be an insufficient intervention window, or the questionnaires may lack the sensitivity to detect gradual change. That gap between biological signal and clinical outcome is the central unresolved question.

Other limitations are worth naming directly. Polypharmacy was common in the cohort, and medication effects on the microbiome could confound the results. Dietary adherence was self-reported and semi-structured, introducing variability. The sample was entirely female, which reflects the epidemiology of fibromyalgia but limits generalizability to men or to other pain conditions. And 16S rDNA sequencing, while standard, restricts taxonomic resolution and cannot assess what the bacteria are actually doing metabolically.

Where This Research Needs to Go Next

The trial's authors call for multi-omics follow-up, incorporating metagenomic, metaproteomic, and metabolomic analyses that could connect specific bacterial shifts to functional outputs like butyrate levels or equol production. Controlling pharmacological variables more rigorously, perhaps through stratified randomization by medication class, would strengthen causal inference. Longer interventions and more sensitive clinical instruments would help determine whether the microbiome changes documented here eventually produce measurable symptom relief.

For now, the study adds a specific and data-grounded tile to a larger mosaic: extra virgin olive oil on a Mediterranean diet does something measurable to the gut microbiome in fibromyalgia patients, with effects that appear to persist and even deepen after the oil is withdrawn. Whether those shifts eventually translate to less pain and better sleep remains an open question, but it is now a more tractable one.

Evidence rating

EMERGING — 84/100

Caveats:

• This trial enrolled only women with fibromyalgia following a Mediterranean diet, so findings may not apply to other populations or dietary backgrounds.
• Microbiota composition shifted with EVOO, but no significant improvements in pain, fatigue, or quality-of-life scores were observed during the intervention period.
• 16S rRNA sequencing identifies which bacteria changed but cannot confirm what those bacteria were doing metabolically — functional impact remains unconfirmed.
• High rates of polypharmacy in participants may have independently influenced gut microbiota composition, making it difficult to isolate the effect of EVOO.
• Funding source was not disclosed by the authors.

Prospective, randomized, double-blind, placebo-controlled trial (n=206 fibromyalgia patients, 44 controls). Demonstrates statistically significant shifts in specific gut bacterial taxa with EVOO supplementation but no significant change in overall microbial diversity or validated clinical outcomes (SF-36, FIQR). Results show association between dietary intervention and microbiota composition, not a proven causal pathway to symptom relief. This is the first trial of its kind in a fibromyalgia population and has not yet been independently replicated.

References

1. Elena Durán González, Jorge Antolín Ramírez Tejero, Ismael San Mauro Martín, et al. (2026). Impact of a Mediterranean Diet Supplemented with Extra Virgin Olive Oil on Gut Microbiota in Fibromyalgia: A Randomized Controlled Trial. Life. https://doi.org/10.3390/life16060894
2. Fibromyalgia – StatPearls – NCBI Bookshelf – NIH. NIH. https://www.ncbi.nlm.nih.gov/books/NBK540989/
3. Zhaohua Wang, Dan Jiang, Min Zhang, Yu Teng, Yaojiang Huang (2024). Causal association between gut microbiota and fibromyalgia: a Mendelian randomization study. Frontiers in Microbiology. https://doi.org/10.3389/fmicb.2023.1305361
4. Jasmine F Millman, Shiki Okamoto, Taiki Teruya, et al. (2021). Extra-virgin olive oil and the gut-brain axis: influence on gut microbiota, mucosal immunity, and cardiometabolic and cognitive health. Nutrition Reviews. https://doi.org/10.1093/nutrit/nuaa148